LBA36 - Association of PD-L1 expression and gene expression profiling with clinical response to pembrolizumab…
jwood@krftwrk.caNovember 14, 2018
LBA12_PR - PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with…
jwood@krftwrk.caNovember 14, 2018
LBA50 - Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III…
jwood@krftwrk.caNovember 14, 2018
LBA67 - Cabozantinib in patients with advanced osteosarcomas and Ewing sarcomas: a French Sarcoma Group…
jwood@krftwrk.caNovember 14, 2018
NACF 2017. P247. Efficacy and Safety of Tezacaftor/Ivacaftor in Patients Aged ≥12 Years with CF…
jwood@krftwrk.caNovember 27, 2017
Multiple Myeloma EHA 2017. LB2236. Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd)…
jwood@krftwrk.caAugust 1, 2017
Multiple Myeloma: CAR-T Cell Therapy ASCO 2017. LBA3001. Durable remissions with BCMA-specific chimeric antigen receptor…
jwood@krftwrk.caAugust 1, 2017
Chronic Lymphocytic Leukemia: Ibrutinib Monotherapy EHA 2017. S769. Long-term Efficacy and Safety with Ibrutinib in…
jwood@krftwrk.caAugust 1, 2017
ASCO 2017. LBA 3. LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy…
jwood@krftwrk.caJuly 10, 2017
